SELECTA BIOSCI(SELB) - 2025 Q4 - Annual Report

Clinical Development and Efficacy - The company has administered Descartes-08 to over 100 patients suffering from autoimmune diseases, with no observed product-related cytokine release syndrome (CRS), neurotoxicity, or infections of any grade[36]. - In the Phase 2a trial, Descartes-08 demonstrated an average improvement in disease severity scores that was three-to-five-fold greater than clinically meaningful thresholds, with clinical improvements persisting in all patients at Month 9[44]. - By Month 6, participants with detectable anti-acetylcholine receptor antibody levels experienced an average 42% reduction in antibody levels, deepening to 68% by Month 9 and persisting at Month 12[46]. - The Phase 2b trial achieved its primary endpoint, with patients receiving six weekly infusions showing a five-point or greater reduction in their Myasthenia Gravis Composite (MGC) score at day 85[47]. - 83% of evaluable participants from the primary efficacy dataset maintained a clinically meaningful response, defined as a reduction in MG-ADL score of at least 2 points, through Month 12[53]. - The safety profile observed in the follow-up portion of the Phase 2b trial was consistent with previous reports, with no new adverse events reported after Month 3 follow-up[54]. - Descartes-08 demonstrated a safety profile with notable adverse events including headaches (35% Grade 1), chills (40% Grade 1), and nausea (15% Grade 1) in the treatment group[56]. - In the Phase 3 AURORA trial, approximately 100 participants will receive Descartes-08 versus placebo, with the primary endpoint assessing improvement in MG-ADL score of three points or more at Month 4[60][62]. - The FDA granted Special Protocol Assessment for the AURORA trial, indicating the trial design is acceptable to support a future Biologics License Application for Descartes-08 in MG[62]. - The company plans to expand Descartes-08 development into myositis, with a Phase 2 trial designed for up to 50 patients, assessing safety and efficacy at Week 24[66][67]. - The Phase 2 trial in systemic lupus erythematosus (SLE) reported significant disease activity reduction, with 100% of participants achieving Lupus Low Disease Activity State at Month 3[78]. Regulatory Designations and Approvals - Descartes-08 has been granted Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation by the FDA for the treatment of Myasthenia Gravis (MG)[32]. - Descartes-08 received Rare Pediatric Disease Designation for juvenile dermatomyositis, potentially qualifying the company for a priority review voucher upon approval[71]. - In January 2025, the FDA provided written agreement under the SPA process for the overall design of the planned Phase 3 AURORA trial for Descartes-08 in MG[120]. - Descartes-08 has also been granted RMAT designation for the treatment of MG[140]. - The FDA aims to review 90% of standard BLAs in 10 months and 90% of priority BLAs in 6 months from the filing date[130]. - The FDA may deny approval of a BLA if it deems the application incomplete or if the data does not support safety and efficacy[129]. - The FDA requires a pediatric assessment for BLAs unless a waiver is obtained, ensuring safety and effectiveness for pediatric populations[124]. - The FDA may suspend or terminate a clinical study at any time due to safety concerns or non-compliance with regulatory requirements[122]. - The FDA may require post-marketing clinical studies to confirm benefits for products approved under accelerated approval[137]. - The FDA offers various expedited programs, including Fast Track and Breakthrough Therapy designations, to facilitate the review of new biological products[135]. - Orphan exclusivity may be lost if the manufacturer cannot ensure sufficient quantities of the drug for patients[134]. Manufacturing and Supply Chain - The company has established in-house manufacturing capabilities, allowing for rapid optimization and control over the supply chain, with a facility in Frederick, Maryland[88][89]. - Descartes-08 is manufactured on a patient-by-patient basis, with processing and release of lots for infusion typically within three weeks[89]. Intellectual Property - As of December 31, 2025, the company had seven issued patents worldwide, including three in the United States and four outside the United States, with expiration dates ranging from 2040 to 2044[90]. - The company has 24 pending patent applications worldwide, including seven in the U.S. and 17 in other jurisdictions, with various expected expiration dates from 2040 to 2046[90]. - The company has 294 issued patents related to legacy Selecta assets, with expiration dates from 2032 to 2040, and 75 pending patent applications worldwide[91]. Financial Considerations and Risks - The company expects to incur losses for the foreseeable future and may never achieve or maintain profitability[190]. - The company has recorded a material amount of goodwill and indefinite-lived intangible assets, which may lead to impairment charges affecting financial results[190]. - The company faces competition from major pharmaceutical companies and smaller biotech firms, which may have greater resources and market presence[105]. - The company relies on third-party payors for coverage and reimbursement, which significantly impacts sales and financial condition[172]. - The company must incur significant costs to develop manufacturing capabilities and may rely on third parties for production[190]. - The company is subject to various risks related to the development of its product candidates, including potential delays and additional costs in clinical trials[193]. - Preclinical development is costly and inherently uncertain, with potential delays or inability to complete clinical development and commercialization of product candidates[194]. - Extensive clinical trials are required to demonstrate safety and efficacy before obtaining marketing approval, which can take many years and is inherently uncertain[195]. - Many companies in the pharmaceutical and biotechnology industries have faced significant setbacks in clinical trials despite positive early results, highlighting the risks involved[196]. - Serious adverse events (SAEs) could lead to interruptions or halts in clinical trials, resulting in delays or denial of marketing approval by regulatory authorities[197]. - Delays in clinical trials can increase product development costs and shorten exclusive commercialization periods, potentially harming business operations[202]. - Enrollment difficulties in clinical trials could delay necessary regulatory approvals and increase development costs, impacting stock value and financing ability[203]. - Conducting clinical trials outside the United States may involve additional regulatory burdens and could affect the acceptance of trial data by the FDA[204]. - The company may seek various designations from regulators to expedite the review process, but there is no guarantee these will be granted or maintained[207]. - Undesirable side effects from product candidates could lead to regulatory interruptions, more restrictive labels, or decreased market acceptance if approved[213]. - The potential for product liability claims due to side effects could significantly harm the company's business and prospects[216]. - Regulatory investigations may delay the approval process for the company's product candidates or impose additional post-approval requirements[215]. - The company faces risks that could prevent achieving or maintaining market acceptance of approved product candidates[218]. Employee and Operational Considerations - The company has 75 full-time employees, with 60% holding advanced degrees (Masters, PhD, or MD) as of December 31, 2025[183]. - The company invests in employee well-being, covering 100% of deductibles and co-insurance payments, and offers equity compensation programs[185]. Regulatory Compliance - The company regards its mRNA-modified products as cell therapy products, subject to regulation as "biologics" by the FDA[112]. - The company is required to comply with extensive regulations governing the development and marketing of its products, including preclinical testing and FDA approval processes[111]. - The company must comply with the EU Clinical Trials Regulation, which requires a centralized application procedure for clinical trial authorization[161]. - The company is subject to GDPR regulations regarding data privacy and security, which could increase compliance costs and impact business operations[162]. - The company must adhere to the federal Anti-Kickback Statute, which prohibits remuneration to induce purchases of items reimbursable under federal healthcare programs[163]. - The company faces potential civil monetary penalties and criminal fines for violations of federal and state fraud and abuse laws[168]. - The company must report certain payments and transfers of value to physicians under the Physician Payments Sunshine Act[167]. - The regulatory pathway for biosimilars related to mRNA-modified cell therapy remains uncertain, as it has not been expressly defined in existing statutes or regulations[147]. Market Environment and Industry Impact - The Inflation Reduction Act of 2022 may significantly affect the pharmaceutical industry, potentially reducing prices and reimbursement rates for approved products[177]. - The EU's health technology assessment regulation, effective from January 12, 2025, will require cooperation among Member States for pricing and reimbursement decisions[173].